Ad

GLS

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad
N/A

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Total Analysts: 0

Company Profile

Gelesis Holdings, Inc., formerly Capstar Special Purpose Acquisition Corp., is a commercial stage biotherapeutics company built for consumer engagement. The Company focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate includes GS200 for weight loss in prediabetes and type two diabetes. It is also developing GS300 for the treatment of NAFLD and NASH, and GS500 for the treatment of FC.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses